Recent VRNA Stock Price | VRNA Stock Predictions | |
$15.31 | +121.16% |
$33.86 |
Recent VRNA Analyst Ratings Breakdown, Making VRNA Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 7 | 7 | 7 | 7 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 0 | 0 | 0 | 0 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 1.0 | 1.0 | 1.0 | 1.0 |
For the VRNA stock predictions from the analysts covering Verona Pharma Plc (Adderbury), we have collected all of the individual VRNA stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 7 different analysts covering VRNA (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since VRNA stock predictions may vary widely, another useful metric to consider is the median VRNA stock prediction, which represents the price at which half of the analysts
made VRNA stock predictions that were higher and half made VRNA stock predictions that were lower. This makes for a different take on the VRNA stock predictions out there, as compared to average or mean.
And that median across all the individual VRNA stock predictions was: $33.0 as of 2024-04-26.
The very highest of the VRNA stock predictions for one year price target was $38.0, while the very lowest of the VRNA stock predictions in the analyst group was
$31.0 (with a standard deviation of $2.544). Get the latest Zacks research report on VRNA — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
VERI Stock Predictions
BNFT Stock Predictions
ETON Stock Predictions
ROP Stock Predictions
SIGI Stock Predictions
OR Stock Predictions
BLK Stock Predictions
SPWR Stock Predictions
HOME Stock Predictions
|
|
Strong Buy (4.00 out of 4) 78th percentile
(ranked higher than approx. 78% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |